| Year |
Citation |
Score |
| 2023 |
Dev A, Vachher M, Prasad CP. β-catenin inhibitors in cancer therapeutics: intricacies and way forward. Bioengineered. 14: 2251696. PMID 37655825 DOI: 10.1080/21655979.2023.2251696 |
0.341 |
|
| 2023 |
Kashyap A, Umar SM, Dev J R A, Mathur SR, Gogia A, Batra A, Deo SVS, Prasad CP. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis. Journal of Cellular Biochemistry. 124: 1259-1272. PMID 37450687 DOI: 10.1002/jcb.30443 |
0.467 |
|
| 2023 |
Prasad CP, Tripathi SC, Kumar M, Mohapatra P. Passage number of cancer cell lines: Importance, intricacies, and way-forward. Biotechnology and Bioengineering. PMID 37439093 DOI: 10.1002/bit.28496 |
0.355 |
|
| 2022 |
Bhat AA, Nisar S, Singh M, Ashraf B, Masoodi T, Prasad CP, Sharma A, Maacha S, Karedath T, Hashem S, Yasin SB, Bagga P, Reddy R, Frennaux MP, Uddin S, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Communications (London, England). PMID 35791509 DOI: 10.1002/cac2.12295 |
0.356 |
|
| 2022 |
Prasad CP, Gogia A, Batra A. Essential role of aerobic glycolysis in epithelial-to-mesenchymal transition during carcinogenesis. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. PMID 35751743 DOI: 10.1007/s12094-022-02851-6 |
0.315 |
|
| 2021 |
Kashyap A, Umar SM, Dev J R A, Prasad CP. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention : Apjcp. 22: 2177-2184. PMID 34319041 DOI: 10.31557/APJCP.2021.22.7.2177 |
0.391 |
|
| 2021 |
Umar SM, Patra S, Kashyap A, Dev J R A, Kumar L, Prasad CP. Quercetin Impairs HuR-Driven Progression and Migration of Triple Negative Breast Cancer (TNBC) Cells. Nutrition and Cancer. 1-14. PMID 34278888 DOI: 10.1080/01635581.2021.1952628 |
0.429 |
|
| 2021 |
Arundhathi JRD, Mathur SR, Gogia A, Deo SVS, Mohapatra P, Prasad CP. Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis. Molecular Biology Reports. PMID 34047880 DOI: 10.1007/s11033-021-06414-w |
0.389 |
|
| 2020 |
Umar SM, Kashyap A, Kahol S, Mathur S, Gogia A, Deo SVS, Prasad CP. Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer. Experimental Cell Research. 112282. PMID 32919954 DOI: 10.1016/j.yexcr.2020.112282 |
0.454 |
|
| 2019 |
Shankar A, Saini D, Dubey A, Roy S, Bharati SJ, Singh N, Khanna M, Prasad CP, Singh M, Kumar S, Sirohi B, Seth T, Rinki M, Mohan A, Guleria R, et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Translational Lung Cancer Research. 8: S106-S121. PMID 31211111 DOI: 10.21037/Tlcr.2019.03.03 |
0.321 |
|
| 2019 |
Shankar A, Dubey A, Saini D, Singh M, Prasad CP, Roy S, Bharati SJ, Rinki M, Singh N, Seth T, Khanna M, Sethi N, Kumar S, Sirohi B, Mohan A, et al. Environmental and occupational determinants of lung cancer. Translational Lung Cancer Research. 8: S31-S49. PMID 31211104 DOI: 10.21037/Tlcr.2019.03.05 |
0.318 |
|
| 2018 |
Singh M, Prasad CP, Singh TD, Kumar L. Cancer research in India: Challenges & opportunities. The Indian Journal of Medical Research. 148: 362-365. PMID 30665997 DOI: 10.4103/Ijmr.Ijmr_1711_18 |
0.341 |
|
| 2018 |
Mohapatra P, Prasad CP, Andersson T. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells. Molecular Oncology. PMID 30582770 DOI: 10.1002/1878-0261.12433 |
0.552 |
|
| 2018 |
Prasad CP, Manchanda M, Mohapatra P, Andersson T. WNT5A as a therapeutic target in breast cancer. Cancer Metastasis Reviews. PMID 30171384 DOI: 10.1007/S10555-018-9760-Y |
0.652 |
|
| 2018 |
Prasad CP, Andersson T. Abstract B021: Inhibition of β-catenin impairs triple-negative breast cancer (TNBC) cell migration and invasion by modulating aerobic glycolysis components Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B021 |
0.629 |
|
| 2017 |
Prasad CP, Södergren K, Andersson T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget. 8: 71471-71488. PMID 29069720 DOI: 10.18632/Oncotarget.17277 |
0.656 |
|
| 2017 |
Canesin G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, Prasad CP, Bjartell A, Andersson T. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. Plos One. 12: e0184418. PMID 28886116 DOI: 10.1371/Journal.Pone.0184418 |
0.595 |
|
| 2017 |
Prasad CP, Södergren K, Andersson T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget. PMID 28488573 DOI: 10.18632/oncotarget.17277 |
0.632 |
|
| 2016 |
Prasad CP, Chaurasiya SK, Guilmain W, Andersson T. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. Journal of Experimental & Clinical Cancer Research : Cr. 35: 144. PMID 27623766 DOI: 10.1186/S13046-016-0421-0 |
0.626 |
|
| 2016 |
Mehdawi LM, Prasad CP, Ehrnström R, Andersson T, Sjölander A. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells. Molecular Oncology. 10: 1415-1429. PMID 27522468 DOI: 10.1016/J.Molonc.2016.07.011 |
0.627 |
|
| 2016 |
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, ... ... Prasad CP, et al. Melanoma and Immunotherapy Bridge 2015 : Naples, Italy. 1-5 December 2015 Journal of Translational Medicine. 14: 65-65. PMID 27461275 DOI: 10.1186/S12967-016-0791-2 |
0.406 |
|
| 2016 |
Linnskog R, Mohapatra P, Moradi F, Prasad CP, Andersson T. Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion. Oncotarget. PMID 27191257 DOI: 10.18632/Oncotarget.9332 |
0.547 |
|
| 2016 |
Moradi F, Berglund P, Linnskog R, Leandersson K, Andersson T, Prasad CP. Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration. Translational Research : the Journal of Laboratory and Clinical Medicine. 172: 45-60. PMID 26970271 DOI: 10.1016/J.Trsl.2016.02.007 |
0.596 |
|
| 2015 |
Prasad CP, Mohapatra P, Andersson T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers. 7: 1900-24. PMID 26393652 DOI: 10.3390/Cancers7030868 |
0.539 |
|
| 2015 |
Andersson T, Axelsson L, Mohapatra P, Prasad C, Soerensen PG, Mau-Soerensen M, Lassen U, Molvadgaard T, Buhl U, Brünner N, Nielsen D. Abstract A116: Targeting the Wnt-5a signaling pathway as a novel anti-metastatic therapy Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A116 |
0.616 |
|
| 2014 |
Linnskog R, Jönsson G, Axelsson L, Prasad CP, Andersson T. Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression. Molecular Oncology. 8: 1365-78. PMID 24954857 DOI: 10.1016/J.Molonc.2014.05.008 |
0.555 |
|
| 2013 |
Prasad CP, Chaurasiya SK, Axelsson L, Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Molecular Oncology. 7: 870-83. PMID 23727359 DOI: 10.1016/J.Molonc.2013.04.005 |
0.607 |
|
| 2010 |
Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. Chemico-Biological Interactions. 183: 455-61. PMID 19944674 DOI: 10.1016/J.Cbi.2009.11.019 |
0.542 |
|
| 2010 |
Prasad C. The Hedgehog Signaling Pathway in Breast Cancer International Journal of Clinical Reviews. DOI: 10.5275/Ijcr.2010.12.03 |
0.468 |
|
| 2009 |
Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. Bmc Cancer. 9: 325. PMID 19751508 DOI: 10.1186/1471-2407-9-325 |
0.474 |
|
| 2009 |
Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chemico-Biological Interactions. 181: 263-71. PMID 19573523 DOI: 10.1016/J.Cbi.2009.06.012 |
0.482 |
|
| 2008 |
Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G, Ralhan R. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sciences. 83: 318-25. PMID 18662704 DOI: 10.1016/J.Lfs.2008.06.019 |
0.349 |
|
| 2008 |
Bagadi SAR, Prasad CP, Kaur J, Srivastava A, Prashad R, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of RASSF1A, RARβ2, BRCA1 and HOXA5 in breast cancers of Indian patients Life Sciences. 82: 1288-1292. PMID 18538349 DOI: 10.1016/J.Lfs.2008.04.020 |
0.429 |
|
| 2007 |
Prasad CP, Gupta SD, Rath G, Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology. 73: 112-7. PMID 18337623 DOI: 10.1159/000120999 |
0.437 |
|
| 2007 |
Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sciences. 81: 280-7. PMID 17599361 DOI: 10.1016/J.Lfs.2007.05.012 |
0.41 |
|
| 2007 |
Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sciences. 80: 1873-81. PMID 17383681 DOI: 10.1016/J.Lfs.2007.02.026 |
0.41 |
|
| 2007 |
Bagadi SAR, Prasad CP, Srivastava A, Prashad R, Gupta SD, Ralhan R. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Research and Treatment. 104: 277-286. PMID 17115114 DOI: 10.1007/S10549-006-9422-6 |
0.488 |
|
| Show low-probability matches. |